RAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent ...

Objective—Glucagon-like peptide 1 (GLP-1 ... Previous studies have focused on the improvements in β-cell function, while the inhibition of α-cell secretion has received less attention.

GLP-1 is a hormone made naturally in the gut. It plays a big role in managing blood sugar and appetite while releasing ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Endometrial cancer (EC) ranks as the second most prevalent gynecologic malignancy globally, with approximately 189,000 new ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

Obesity is a growing concern worldwide, including in low- and middle-income countries (LMICs). Addressing this issue involves various strategies, including dietary and lifestyle changes, medical ...

"Palatin concludes Phase II trial of combination therapy for obesity" was originally created and published by Clinical Trials ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...